Six notes:
1. Quarterly sales rose 2.8% year over year.
2. Medtronic’s cranial and spinal technologies segment saw $1.1 billion in quarterly sales, an increase of 4% year over year.
3. The company’s neuroscience portfolio saw $2.3 billion in sales, up 4.4% year over year.
4. Medtronic’s medical surgical portfolio grew 0.4% year over year with $2 billion in sales. The cardiovascular portfolio saw $3 billion in sales, a 5.5% increase year over year.
5. Medtronic raised its guidance for fiscal year 2025 and expects to see full-year growth of 4.5% to 5% year over year.
6. Net income was $1 billion, a 32% increase year over year.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
